Data updated: Mar 10, 2026
NOCDURNA
DESMOPRESSIN ACETATE
Approved 2018-06-21
1
Indication
--
Phase 3 Trials
7
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2018-06-21
- Routes
- SUBLINGUAL
- Dosage Forms
- TABLET
NOCDURNA Approval History
Loading approval history...
What NOCDURNA Treats
1 FDA approvalsOriginally approved for its first indication in 2018 .
- Other (1)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
NOCDURNA FDA Label Details
ProNOCDURNA Patents & Exclusivity
Latest Patent: Apr 2030
Patents (12 active)
US9974826
Expires Apr 13, 2030
US11963995
Expires May 21, 2029
US10137167
Expires May 21, 2029
US11020448
Expires May 21, 2029
+ 2 more patents
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.